Tg Therapeutics share price today

(TGTX)

Tg Therapeutics share price is $32.2 & ₹2,736.23 as on 21 Dec 2024, 2.30 'hrs' IST

$32.2

▲

1.25

(4.04%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Tg Therapeutics share price in Dollar and Rupees. Guide to invest in Tg Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Tg Therapeutics. Get details on the Indian mutual funds that are investing in Tg Therapeutics. Get Analyst recommendations and forecasts along with all the Tg Therapeutics's financials.

Tg Therapeutics share price movements

Today's Low: $30.65
Today's High: $32.63
$32.20
4.81%
Downside
Day's Volatility :6.05%
Upside
1.3%
52 Weeks Low: $12.84
52 Weeks High: $36.84
$32.20
60.12%
Downside
52 Weeks Volatility :65.15%
Upside
12.6%

Tg Therapeutics Returns

Period	Tg Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	38.49%	-11.1%	0.0%
6 Months	74.9%	-6.0%	0.0%
1 Year	89.52%	2.7%	0.0%
3 Years	66.06%	0.6%	-19.7%

Tg Therapeutics Key Statistics

in dollars & INR

Previous Close	$30.95
Open	$30.6
Today's High	$32.625
Today's Low	$30.65
Market Capitalization	$4.8B
Today's Volume	$2.6M
52 Week High	$36.84
52 Week Low	$12.84
Revenue TTM	$264.8M
EBITDA	$-408.0K
Earnings Per Share (EPS)	$-0.1
Profit Margin	-5.43%
Quarterly Earnings Growth YOY	-0.97%
Return On Equity TTM	-8.05%

How to invest in Tg Therapeutics from India?

It is very easy for Indian residents to invest directly in Tg Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Tg Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Tg Therapeutics or TGTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Tg Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Tg Therapeutics shares which would translate to 0.026 fractional shares of Tg Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Tg Therapeutics, in just a few clicks!

Returns in Tg Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Tg Therapeutics investment value today

Current value as on today

₹1,91,719

Returns

₹91,719

(+91.72%)

Returns from Tg Therapeutics Stock

₹89,523 (+89.52%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Tg Therapeutics

-42%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Tg Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 22, 2024. -42% less investors are searching Tg Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Tg Therapeutics

Vanguard Group Inc
9.88%
BlackRock Inc
7.32%
State Street Corp
5.84%
Pictet Asset Manangement SA
2.30%
Geode Capital Management, LLC
2.06%
Woodline Partners LP
1.65%

Analyst Recommendation on Tg Therapeutics

Buy

80%Buy

13%Hold

6%Sell

Based on 15 Wall street analysts offering stock ratings for Tg Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Tg Therapeutics

What analysts predicted

Upside of 26.55%

Current:

$32.20

Target:

$40.75

Insights on Tg Therapeutics

Price Movement
In the last 6 months, TGTX stock has moved up by 82.4%
Increasing Revenue
Revenue is up for the last 4 quarters, 43.97M → 83.87M (in $), with an average increase of 18.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 6.87M → 3.88M (in $), with an average decrease of 43.6% per quarter

Tg Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$152.0K	↓ 0.25%
Net Income	$-173.5M	↑ 46.43%
Net Profit Margin	-114.1K%	↓ 36383.03%

	FY19	Y/Y Change
Revenue	$152.0K	↑ 0.0%
Net Income	$-179.3M	↑ 3.38%
Net Profit Margin	-118.0K%	↓ 3858.56%

	FY20	Y/Y Change
Revenue	$152.0K	↑ 0.0%
Net Income	$-285.9M	↑ 59.4%
Net Profit Margin	-188.1K%	↓ 70086.18%

	FY21	Y/Y Change
Revenue	$6.7M	↑ 4300.66%
Net Income	$-355.6M	↑ 24.37%
Net Profit Margin	-5.3K%	↑ 182762.16%

	FY22	Y/Y Change
Revenue	$2.8M	↓ 58.36%
Net Income	$-203.8M	↓ 42.67%
Net Profit Margin	-7.3K%	↓ 2003.42%

	FY23	Y/Y Change
Revenue	$233.7M	↑ 8290.02%
Net Income	$12.7M	↓ 106.22%
Net Profit Margin	5.42%	↑ 7324.31%

	Q2 FY23	Q/Q Change
Revenue	$16.1M	↑ 106.0%
Net Income	$-47.6M	↑ 23.25%
Net Profit Margin	-296.19%	↑ 198.85%

	Q3 FY23	Q/Q Change
Revenue	$165.8M	↑ 931.57%
Net Income	$113.9M	↓ 339.3%
Net Profit Margin	68.71%	↑ 364.9%

	Q4 FY23	Q/Q Change
Revenue	$44.0M	↓ 73.48%
Net Income	$-14.4M	↓ 112.65%
Net Profit Margin	-32.79%	↓ 101.5%

	Q1 FY24	Q/Q Change
Revenue	$63.5M	↑ 44.35%
Net Income	$-10.7M	↓ 25.73%
Net Profit Margin	-16.87%	↑ 15.92%

	Q2 FY24	Q/Q Change
Revenue	$73.5M	↑ 15.74%
Net Income	$6.9M	↓ 164.25%
Net Profit Margin	9.36%	↑ 26.23%

	Q3 FY24	Q/Q Change
Revenue	$83.9M	↑ 14.17%
Net Income	$3.9M	↓ 43.6%
Net Profit Margin	4.63%	↓ 4.73%

	FY18	Y/Y Change
Profit	$64.0K	↓ 58.0%

	FY19	Y/Y Change
Profit	$-130.0K	↓ 303.12%

	FY20	Y/Y Change
Profit	$-222.0K	↑ 70.77%

	FY21	Y/Y Change
Profit	$5.9M	↓ 2757.21%

	FY22	Y/Y Change
Profit	$2.5M	↓ 57.28%

	FY23	Y/Y Change
Profit	$219.1M	↑ 8594.76%

	Q2 FY23	Q/Q Change
Profit	$14.2M	↑ 103.9%

	Q3 FY23	Q/Q Change
Profit	$162.3M	↑ 1045.99%

	Q4 FY23	Q/Q Change
Profit	$36.0M	↓ 77.8%

	Q1 FY24	Q/Q Change
Profit	$58.0M	↑ 60.86%

	Q2 FY24	Q/Q Change
Profit	$65.1M	↑ 12.32%

	Q3 FY24	Q/Q Change
Profit	$74.5M	↑ 14.52%

	FY18	Y/Y Change
Operating Cash Flow	$-128.9M	↑ 37.5%
Investing Cash Flow	$1.2M	↓ 114.38%
Financing Cash Flow	$113.6M	↓ 14.98%

	FY19	Y/Y Change
Operating Cash Flow	$-132.8M	↑ 3.01%
Investing Cash Flow	$-718.0K	↓ 160.85%
Financing Cash Flow	$204.2M	↑ 79.7%

	FY20	Y/Y Change
Operating Cash Flow	$-214.5M	↑ 61.52%
Investing Cash Flow	$-24.5M	↑ 3313.65%
Financing Cash Flow	$679.8M	↑ 232.9%

	FY21	Y/Y Change
Operating Cash Flow	$-295.6M	↑ 37.82%
Investing Cash Flow	$-332.0K	↓ 98.65%
Financing Cash Flow	$41.4M	↓ 93.91%

	FY22	Y/Y Change
Operating Cash Flow	$-176.2M	↓ 40.41%
Investing Cash Flow	$-20.0M	↑ 5928.01%
Financing Cash Flow	$-391.0K	↓ 100.94%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-42.0M	↓ 29.88%
Investing Cash Flow	$30.5M	↓ 594.5%
Financing Cash Flow	$47.0M	↑ 86.41%

Tg Therapeutics Technicals Summary

Sell

Neutral

Buy

Tg Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Tg Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Tg Therapeutics Inc	-8.18%	74.9%	89.52%	66.06%	187.5%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.38%	12.23%	86.41%
Biontech Se	4.48%	30.56%	7.97%	-55.71%	237.85%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.37%	26.29%	108.55%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-2.55%	77.79%	80.12%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Tg Therapeutics Inc	39.29	NA	0.0	0.2	-0.08	0.0	NA	1.34
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Tg Therapeutics Inc	Buy	$4.8B	187.5%	39.29	-5.43%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	86.41%	17.51	33.61%
Biontech Se	Buy	$26.7B	237.85%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	108.55%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.12%	32.84	-4.51%

About Tg Therapeutics

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".

Organization	Tg Therapeutics
Employees	319
CEO	Mr. Michael S. Weiss Esq.
Industry	Health Technology

Management People of Tg Therapeutics

Name	Title
Mr. Michael S. Weiss Esq.	Chairman, CEO & President
Mr. Sean A. Power CPA	CFO, Corporate Secretary & Treasurer
Ms. Jenna Bosco	Senior Vice President of Corporate Communications
Mr. Adam Waldman	Chief Commercialization Officer

Important FAQs about investing in Tg Therapeutics from India :

What is Tg Therapeutics share price today?

Tg Therapeutics share price today stands at $32.20, Open: $30.60 ; Previous Close: $30.95 ; High: $32.63 ; Low: $30.65 ; 52 Week High: $36.84 ; 52 Week Low: $12.84. The stock opens at $30.60, after a previous close of $30.95. The stock reached a daily high of $32.63 and a low of $30.65, with a 52-week high of $36.84 and a 52-week low of $12.84.

Can Indians buy Tg Therapeutics shares?

Yes, Indians can invest in the Tg Therapeutics (TGTX) from India.

With INDmoney, you can buy Tg Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Tg Therapeutics at zero transaction cost.

How can I buy Tg Therapeutics shares from India?

It is very easy to buy Tg Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Tg Therapeutics be purchased?

Yes, you can buy fractional shares of Tg Therapeutics with INDmoney app.

What are the documents required to start investing in Tg Therapeutics stocks?

To start investing in Tg Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.